title: [Cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion for peritoneal carcinomatosis caused by recurrent inflammatory myofibroblastic sarcoma: a case report and review of the literature].
abstract: Peritoneal carcinomatosis is a fatal diagnosis, associated with poor prognosis and quality of life. Survival is usually estimated in month. Traditionally surgery for peritoneal carcinomatosis was indicated only for palliative effort. Advances in tumour biology, cytoreductive surgery and pharmacology have improved the approach for this condition. An aggressive combined approach to peritoneal surface malignancy involves peritonectomy and intraperitoneal perioperative hyperthermic chemotherapy. Cytoreductive surgery reduces carcinomatosis to microscopic residual disease so that intraperitoneal hyperthermic chemotherapy is able to eradicate cancer. Hyperthermic chemotherapy enhances the cytotoxicity of the drugs and increases their penetration into the cancerous tissue. Careful patient selection is crucial for this multimodality approach. Quantitative prognostic indicators are useful in the assessment of outcome, like peritoneal cancer index and completeness of cytoreduction score. Cytoreductive surgery combined with intraperitoneal hyperthermic chemotherapy improves survival but is associated with significant morbidity and mortality. This review is based on a case report of a 22-year-old female patient who had peritoneal carcinomatosis of inflammatory myofibroblastic sarcoma and was treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy at our department.
authors.affiliation: Országos Onkológiai Intézet, Altalános es Mellkassebészeti Osztály. matraidok@freemail.hu
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Mátrai
authors.forename: Gábor
authors.initials: G
authors.lastname: Péley
authors.forename: Tibor
authors.initials: T
authors.lastname: Kovács
authors.forename: Vámos Ferenc
authors.initials: VF
authors.lastname: Rényi
authors.forename: Edit
authors.initials: E
authors.lastname: Szívós
authors.forename: Eszter
authors.initials: E
authors.lastname: Szabó
authors.forename: Ildikó
authors.initials: I
authors.lastname: Vereczkey
authors.forename: Klára
authors.initials: K
authors.lastname: Török
authors.forename: István
authors.initials: I
authors.lastname: Köves
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000009:adverse effects / Q000379:methods; D005260:Female; D006801:Humans; D006979:Hyperthermia, Induced / Q000009:adverse effects; D007249:Inflammation; D007430:Intraoperative Care / Q000379:methods*; D009217:Myosarcoma / Q000556:secondary*; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery / Q000628:therapy*; D011379:Prognosis